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Mehmet Ali Koc, Suleyman Utku Celik and Cihangir Akyol
Abstract
Colorectal cancers (CRCs) are commonly diagnosed malignancy in both 
men and women. Although it is a common disease, mortality rates decrease with 
widespread use of screening methods and novel developments in surgery. Physical 
examination, abdomen and pelvic computerized tomography, and chest imaging 
are necessary for preoperative staging and surgical planning of a newly diagnosed 
colon cancer. CRCs usually develop from adenomatous polyps. Although curative 
treatment of localized colon cancer is surgery, endoscopic polypectomy is suf-
ficient when severe dysplasia or carcinoma in situ is detected on a polyp surface. 
Total mesorectal excision and neoadjuvant chemoradiotherapy in rectum cancers 
resulted in significant reductions in morbidity, mortality, and recurrence rates. 
Recently, complete mesocolic excision and central vascular ligation method has 
been described in the surgical treatment of colon cancer to achieve similar results. 
Unfortunately, metastatic colon cancer rate at presentation is approximately 20%. 
Surgery is a potentially curative option in selected patients with liver and lung 
metastasis. Pathologic stage of the tumor at presentation is the most important 
prognostic factor after resection. Therefore, early diagnosis of colon cancer by 
screening methods and new surgical techniques will lead to better results in sur-
vival rates.
Keywords: colon cancer, central vascular ligation, complete mesocolic excision, 
prevention, treatment
1. Introduction
Colorectal cancer (CRC) is the second most common cancer in women and 
third in men with an estimation of approximately 1.4 million new cases globally [1]. 
Men are more affected than women in most of the world with a higher incidence in 
North America and Europe and, lower incidence in South-Central Asia and Africa 
[1]. Although it is a common disease, mortality rates decrease with novel develop-
ments in surgery and widespread use of screening methods such as colonoscopy, 
computed tomography colonoscopy, fecal occult blood test. In the United States, 
decrease in CRC mortality rates has been shown in the Survey of Epidemiology 
and End Results (SEER) program [2]. Due to comprehensive researches about the 
biological and molecular characteristics of CRC, cancer pathogenesis has been well 
elucidated. Since CRC develops after a long process under the influence of both 
genetic and environmental factors, early diagnosis is possible and as a result there 
are better treatment outcomes and prognosis [1–3].
Colorectal cancer incidence rises steadily after the age of 50 years and most of 
the cases are diagnosed in 6th and 7th decades. The incidence under age 40 years is 
only 5% [3]. Although it is recommended to initiate screening studies at 50 years 
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age, suspicious symptoms like rectal bleeding, unexplained anemia, change in 
bowel habits, and weight loss should be investigated regardless of the individual’s 
age. Approximately 80% of CRCs are sporadic, 15% are non-syndromic familial, 
and 5% are syndromic familial cancers [3–5].
CRC is more common in developed societies that consume high-calorie diets 
rich in animal fat, red meat, processed meat, sweets, refined grains, and alcohol. 
However a diet rich in fiber, vegetables, fruits, fish, dairy products, and olive oil 
is beneficial to prevent CRC [4, 5]. The consumption of vegetable fibers shortens 
the period of contact of the carcinogenic substances with the colon mucosa and at 
the same time increases the fecal volume and leads to the dilution of the harmful 
substances so that the adverse effect on the mucosa is reduced. The fat-rich diet 
stimulates bile acid and cholesterol synthesis in the liver, the amount of these sterols 
in the colon increases. Due to colon bacteria, production of secondary bile acids 
and other toxic metabolites are increased and causes negative effects on the colon 
mucosa [3, 6]. The intake of A, C, E vitamins, calcium, selenium, and carotenoids is 
thought to reduce the risk of developing CRC [5, 6]. The risk of developing CRC in 
obese and sedentary individuals also increases like other cancers [7]. Furthermore, 
chronic alcohol consumption and smoking have been reported to increase the risk 
of colon adenomas.
The risk of developing CRC in individuals with long-standing inflammatory 
bowel disease is significantly increased [8]. It is thought that chronic inflamma-
tion of the mucosa is a predisposing factor for CRC. Extent and the duration of 
the colitis is closely related with the development of CRC. While the cumulative 
risk of CRC in ulcerative colitis patients with pancolitis or left-sided disease 
is 1.6% at 10 years, it increases approximately 5 times at 20 years (8.3%), and 
11 times at 30 years (18.4%) [9]. A similar risk for CRC is also associated with 
Crohn’s disease. Screening colonoscopy for CRC has been recommended annually 
for patients with inflammatory bowel disease, 8–10 years after the first symptoms 
of the disease [10].
2. Pathogenesis
Most CRCs usually develop from adenomatous polyps that become dysplastic 
(adenoma-carcinoma sequence) (Figures 1 and 2). The epithelium of small bowel 
is constantly renewed. During this renewal process, progressive deterioration 
leads primarily to adenomatous polyps and later to dysplasia and invasive cancer. 
Hypothesis that CRC are a result of adenoma-carcinoma sequence are supported 
by findings such as frequent early carcinoma detection in large adenomatous 
polyps, detection of adenomas in patients 10 years before cancer in both sporadic 
and familial cases, and reduction of CRC incidence by removal of polyps in 
controlled trials [11].
CRCs occur by accumulation of epigenetic and genetic changes over time [12]. 
These changes transform normal glandular epithelium into adenocarcinoma. In 
hereditary forms of CRC, individuals are born with mutant genes. That means the 
mutant gene is present in one allele in the zygote from the beginning (germ-line 
mutation) but a second hit needed. Hereditary non-polyposis colorectal cancer 
(HNPCC) and familial adenomatous polyposis (FAP) are the best known types of 
hereditary CRC. Sometimes mutations develop after birth due to environmental 
factors (somatic mutation) and sporadic cancers occur [10–13].
Tumor suppressor gene mutations may remove an inhibitory signal while onco-
genic mutations may cause overexpression of a gene or pathway [11]. These changes  
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that cause CRC, which is a different heterogenous disease in each person, 
affect the phenotype of the disease, prognosis and response to treatment. 
Chromosomal instability, microsatellite instability, and the methylator pheno-
type are the three major molecular pathways that involved in CRC development. 
Figure 1. 
Adenoma—carcinoma sequence.
Figure 2. 
Adenoma—carcinoma sequence (figure taken from with permission of Prof. Kuzu, Turkish Society of Colon 
and Rectal Surgery; Colon and Rectum Cancers.Eds, Baykan A, Zorluoglu A, Gecim E, Terzi C. 2010).
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Each pathway has unique characteristics, and multiple pathways may play a role in 
the  development of CRC [12, 13].
2.1 Chromosomal instability
Chromosomes are unstable in chromosomal instability (CIN), because of a 
change in the chromosome structure or copy number (Loss of heterozygosity-LOH). 
CIN is the most common occurrence in CRC [13]. Approximately 80% of CRC 
patients have CIN. Vogelstein and Fearon described the classical adenoma-carcinoma 
sequence and their study supported that LOH was responsible for the sequence [14]. 
The main genes which play role in the carcinogenesis are the adenomatous polyposis 
coli (APC), K-ras, deleted in colon cancer (DCC), and P53 (Figure 1).
The APC is a tumor suppressor gene, therefore, mutation in both alleles are 
necessary for the initiation of the sequence. Mutated APC causes decreased produc-
tion or lack of APC protein. Thus, translocation into the nucleus due to intracellular 
accumulation of β-caterin, which is controlled by the APC protein to regulate the 
WNT signaling pathway, causes alterations in cell signaling, proliferation, and 
adhesion [15]. The APC gene is first described in patients with FAP. However, it was 
then reported that majority of the sporadic CRC has the APC gene mutation and 
APC mutation is present in adenomas smaller than 0.5 cm [16].
K-ras is a cellular variant of RAS oncogenes and the most frequently mutated 
RAS proto-oncogene in CRC. Since K-ras is a proto-oncogene, mutation of only 
one allele is enough. K-ras gene encodes a G-protein (Guanine nucleotide binding 
protein) that is active when GTP bond state and inactive (GDP-bond state) after 
hydrolyzed by GTPase. This protein is involved in mitogen-activated protein kinase 
(MAPK) pathway which promotes cell growth and proliferation. RAS mutation 
results in an active GTP-bond protein, which is unable to switch off by GTPase, and 
leads to uncontrolled cell division. About 43% of non-hypermutated (Microsatellite 
stabile-MSS) CRC, which are nearly 80% of CRC, has RAS mutations [17].
DCC and SMAD4 mutations have been found in CRCs [18, 19]. Both are tumor 
suppressor genes. DCC gene product is thought to be involved in cell differentiation 
and adhesion in CRC [20]. DCC and SMAD4 (formerly PC4-deleted in pancreatic 
cancer) were both identified at 18q. SMAD4 mutations is thought to perturb TGF-beta 
signaling pathway which has an inhibitory influence on normal cell growth [19, 20].
TP53 gene on chromosome 17p encode P53 protein which arrests the cell cycle 
and facilitates DNA repair [21]. In all human cancers most of the mutations occur 
in TP53 gene. TP53 mutation occurs in about 75% of CRCs [14]. However it is not 
frequent in adenomas, therefore, it is considered to be a late event in CRC tumori-
genesis and related with invasiveness [22, 23].
2.2 Microsatellite instability (MSI)
Microsatellites are non-coding DNA segments containing 1 to 4 repetitive 
nucleotide sequences. In normal individuals microsatellites are completely identical 
in all cells. But the failure of the DNA mismatch repair genes to function properly 
causes a change in the length of the microsatellite sites that are already prone to 
error during copying. This is called microsatellite instability. There are also short 
repetitive segments in various tumor suppressor genes (TSG), and accumulation of 
the mutations in TSGs due to the inactivity of MMR genes (most commonly MLH1 
or MSH2) lead to the development of adenoma and subsequent carcinoma [21–23].
It is possible to detect microsatellite instability with current diagnostic proce-
dures, as long as many cells carry the same abnormality, which means that the cells 
5Colon Cancer
DOI: http://dx.doi.org/10.5772/intechopen.81597
belong to the clonal process. Clonal proliferation is a characteristic feature of the 
neoplastic process. And It should be understood that MSI is an indicator of a clonal 
neoplastic process [24].
Cancers arising through MSI pathway are approximately 15% of all CRC and 
tend to be hypermutated, therefore, are also termed the mutator phenotype [17]. 
However, prognosis is better than cancers arising through CIN pathway.
2.3 CpG island methylator phenotype (CIMP)
Another common pathway in CRC is epigenetic instability. Epigenetic 
alterations such as hypermethylation of DNA promoter regions can silence gene 
transcription and contributes to diseases like cancer. Methylation of cytosine 
is normally an essential process and controls multiple processes [25]. There are 
cytosine-guanine (CpG) dinucleotide enriched areas in promoter regions. These 
CpG enriched regions of genes are called CpG islands and normally maintained 
in an unmethylated state. Several tumor suppressor genes contain CpG repetitive 
sequences in the promoter region. Aberrant methylation of these CpG islands 
silences gene transcription and contributes to cancer process [25, 26]. This phenom-
enon is called CpG island methylator phenotype (CIMP). Especially methylation 
of the MMR gene, hMLH1 causes approximately 80% of MSI CRCs [27]. Almost all 
MSI-high (MSI–H), CIMP+ cancers without K-ras mutations have BRAF mutations. 
However, Lynch-related CRCs only have K-ras mutations [28, 29].
3. Hereditary colorectal cancers
3.1 Hereditary non-polyposis colorectal cancer (HNPCC)
HNPCC is the most common hereditary colorectal cancer. HNPCC is also 
termed Lynch syndrome. In Lynch syndrome, CRC and endometrial cancer 
risk are significantly increased as well as several other malignancies. It accounts 
for 3% of all colorectal cancers [30]. Lynch is an autosomal dominant disease. 
Mutations in DNA repair genes (mismatch repair-MMR) are detected in affected 
individuals. In Lynch syndrome there is a germline mutation. Since this mutation 
is only in one allele, a second hit is necessary (mutation, loss of heterozygosity, 
or epigenetic silencing). Colorectal cancer develops in 80% of patients around 
40 years of age. The most frequently mutated MMR genes in HNPCC were MLH 1 
(37%), MSH 2 (41%), MSH 6, and PMS 2. CRCs developed in Lynch syndrome are 
MSI-H tumors [30].
In patients with Lynch syndrome, the risk of synchronous and metachronous 
tumors is increased, and approximately 7% of patients have a second tumor at the 
time of diagnosis [31]. Metachronous tumors develop within 10 years in 16% of 
individuals who had previously undergone colon resection due to Lynch syndrome 
and within 30 years this rate reaches to 62% [32].
Lynch-associated CRCs also evolve from adenomas like most CRCs. However the 
adenomas are more often proximally located, and more likely to be larger and flat-
ter. And as compared with sporadic adenomas, high-grade dysplasia and/or villous 
histology are more often detected. It is also known that the adenoma-carcinoma 
sequence progresses more rapidly in Lynch syndrome. Fortunately, the overall 
10-year survival from CRC is 91% [33].
Tumors in HNPCC are more often found in the proximal colon than sporadic 
cancers. Unlike sporadic cancers, tumor in Lynch is poor differentiated and there is 
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peritumoral lymphocytic infiltration, and Crohn’s-like reaction [34]. However, the 
prognosis is still better than sporadic colorectal cancer. The following three theories 
stand out for this reason: earlier diagnosis in HNPCC tumors, the genomic insta-
bility in HNPCC tumors leads to the continual increase of mutations and the loss 
of critical functions and metastatic ability of the tumor cell due to this mutation 
burden, and Crohn’s-like lymphocytic infiltration around the tumor enhances host 
immunity by expressing IL-4, TNF-a [33, 34].
Two different forms of HNPCC have been described. Lynch Syndrome I is 
characterized with proximal colon tumor, young age, no extracolonic involve-
ment. Generally same colonic segment is involved in other relatives. In Lynch 
Syndrome II, in addition to Lynch I, stomach, small intestine, pancreas, ovary, 
endometrium and urinary tract cancers may develop. The most important tool in 
diagnosing Lynch syndrome is family history of CRC or other cancers related with 
Lynch. Several family history-based criteria (Revised Bethesda Guidelines and 
Amsterdam II Criteria) have been used to determine the people at risk for HNPCC 
(Table 1) [34].
MSI is a characteristic of tumors in HNPCC and caused by a loss of DNA 
MMR. An MSI screening test is required for patients with a positive Bethesda cri-
teria. Polymerase chain reaction is used to test for MSI by copying a panel of DNA 
sequences that contains nucleotide repeats [33–35]. Family members who meet the 
Amsterdam II criteria or revised Bethesda guidelines, or those with a diagnosis of 
endometrium cancer prior to the age of 50 years, or individuals with a MMR gene 
mutation in the first degree relatives are at risk for Lynch syndrome.
In Lynch syndrome, synchronous or metachronous cancer and polyp devel-
opment are common. It is important to be cautious in this regard. Colonoscopy 
should be done every one or two years starting from the age of 20–25 [36, 37]. 
Gynecological examination and endometrial aspiration biopsy for endometrium 
cancer, and transvaginal ultrasonography for ovarian cancer should be done once a 
Amsterdam II Criteria and Revised Bethesda Guidelines
Amsterdam II Criteria [35]
All criteria must be met:
• Three or more individuals with colorectal cancers or HNPCC-related cancers, and one of them being 
a first-degree relative of the other two,
• Two or more successive generations are affected,
• At least one relative has colorectal or HNPCC-related cancer diagnosed before the age of 50 years.
Revised Bethesda Guidelines [34]
One or more of the following criteria must be met:
• Colorectal cancer diagnosed before the age of 50 years,
• Synchronous or metachronous colorectal cancer or other HNPCC-related tumors*, regardless of age,
• Colorectal cancer with MSI-high histology** diagnosed before the age of 60 years
• Colorectal cancer diagnosed in one or more first degree relatives with HNPCC-related tumor, and one 
of them being diagnosed before the age of 50 years,
• Colorectal cancer in 2 or more first- or second-degree relatives with HNPCC-associated tumors, 
regardless of age.
HNPCC: hereditary nonpolyposis colorectal cancer; MSI: microsatellite instability. 
*HNPCC-related tumors include colorectal, endometrial, stomach, ovarian, pancreas, ureter and renal pelvis, 
biliary tract, and brain (usually glioblastoma as seen in Turcot syndrome) tumors, sebaceous gland adenomas and 
keratoacanthomas in Muir-Torre syndrome, and carcinoma of the small bowel.
**Presence of tumor-infiltrating lymphocytes, Crohn’s-like lymphocytic reaction, mucinous/signet-ring cell 
differentiation, or medullary growth pattern.
Table 1. 
Amsterdam II Criteria and Revised Bethesda Guidelines.
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year starting from the age of 30–35, or 3–5 years prior to the age of a relative diag-
nosed with HNPCC [37]. Upper gastrointestinal endoscopy should be done once 
every 2 years starting from the age of 30–35, with gastric biopsy and treatment for 
Helicobacter pylori infection when found on biopsy. Renal ultrasound, urine analysis 
and cytology should be done every year starting from the age of 30–35 [36, 37].
3.1.1 Treatment
Prophylactic colectomy is not considered in patients without CRC. Tumor is 
usually located in the proximal colon. Total abdominal colectomy—ileorectal anas-
tomosis is recommended in patients with Lynch syndrome. Considering the quality 
of life in elderly patients, or in patients who are not eligible for total colectomy a 
segmental colectomy may be recommended according to the location of the tumor 
[36]. However patients who undergo segmental colectomy are at increased risk for 
subsequent CRC as compared to patients with total abdominal colectomy—ileorec-
tal anastomosis [38, 39]. Prophylactic hysterectomy and oophorectomy should be 
recommended at the time of colorectal surgery. However, it may be recommended 
for women who aged 35 years or older after family planning [39].
3.2 Familial adenomatous polyposis (FAP)
It accounts for 1% of all colorectal cancers and is an autosomal dominant disease. 
FAP is characterized by the presence of hundreds of adenomas in the colon (Figure 3). 
It is a broad spectrum disease with extraintestinal manifestations. It usually occurs after 
puberty and is diagnosed at a mean age of 29 years. Colorectal cancer develops at an 
average age of 39 years. Colorectal cancer is unavoidable in patients who do not undergo 
surgery. FAP is 80% familial, and 20% sporadic [40].
Mutation in the APC (adenomatous polyposis coli) gene, which is located at the 
q21 locus of chromosome 5, is responsible for FAP (5q deletion) [40, 41]. Mutations 
in codons close to the 3‘and 5’ ends of the APC gene lead to attenuated FAP (AFAP), 
while mutations in the middle, between codons 169 to 1393, result in FAP. Generally, 
there is less than 100 polyps in AFAP. Unlike FAP, life-long risk for CRC develop-
ment in AFAP is approximately 70%, and polyps and CRCs develop later in life than 
FAP. In AFAP, tumors mostly do not develop in the rectum and are characterized by 
a more proximal distribution in the colon. If germline mutation is absent in these 
patients, MMR gene mutation should be considered for HNPCC elimination [41]. In 
Figure 3. 
Colonoscopic familial adenomatous polyposis (FAP).
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FAP, one inherited mutant allele is not enough to cause carcinoma. Carcinoma devel-
ops when the second allele of APC and other necessary gene mutations occur [42].
Extraintestinal manifestations of FAP include gastric, duodenal, and peri-
ampullary polyps, and less common manifestations such as epidermoid cysts, 
desmoid tumors, osteomas, and brain tumors. Gastric and duodenal polyps occur 
in about half of affected individuals. Most of the gastric polyps are hyperplasia 
of the fundus glands, rather than adenomatous polyps and their malignancy 
potential is limited [43]. However duodenal polyps are adenomatous. They are 
present in approximately 90% of FAP patients and should be considered prema-
lignant [44, 45]. Periampullary tumor risk is higher in FAP patients. In patients 
who undergo total colectomy, the most important cause of cancer-related death 
is duodenal adenocancer. Adenomatous polyps and cancer are rarely found in the 
jejunum and ileum of FAP patients. Other rare extraintestinal malignancies in FAP 
patients are extrahepatic bile duct, gallbladder, pancreas, adrenal, thyroid, and 
liver cancers [45].
The likelihood of a desmoid tumor is increased especially in mutations in the 3‘ 
end of the APC gene [46]. Most of the desmoid tumors occur within the first 5 years 
in patients who have undergone abdominal surgery, presumably as an inflammatory 
response [47, 48]. In addition to abdominal surgery and APC mutation, pregnancy, 
female sex, and family history are other risk factors for desmoid tumors [49, 50]. 
Although desmoid tumors are slow growing, non-metastatic mesenchymal tumors, 
they may cause complications such as pain, bowel, and ureter obstruction by 
compressing and encasing adjacent structures [50].
An interesting marker for FAP is congenital hypertrophy of the retinal pigment 
epithelium (CHRPE), which can be determined by ophthalmoscopy in about 75% 
of patients [51]. Fundus examination with ophthalmoscopy reveals oval, pigmented 
lesions with regular borders in the retina. Lesions may be bilateral and multiple. 
CHRPE can be used as a clinical diagnostic tool in the screening of FAP and Gardner 
syndrome [51].
FAP has two subtypes with their own extracolonic manifestations. Gardner’s 
syndrome is a variant of FAP and characterized by desmoid tumors, colonic pol-
yps, osteoma, soft tissue sarcomas, and CHRPE [52]. Also, although very rare, an 
adenomatous polyposis coli may be associated with malignant tumors of the central 
nervous system (especially medulloblastoma and/or glioma), known as Turcot 
syndrome [53]. Turcot is the true variant form of FAP and has a familial character. 
Colonoscopy and brain scanning tests should also be performed on family mem-
bers. APC mutations are also responsible for both syndromes.
Screening for FAP should be performed in individuals with an APC mutation 
and in individuals who are first-degree relatives of those with FAP, or who have 
>10 cumulative colorectal adenomas, or colorectal adenomas in combination with 
extracolonic features such as duodenal adenomas, desmoid tumors, osteomas, etc. 
[53, 54].
Screening for CRC should begin during puberty and flexible sigmoidoscopy, or 
genetic testing for APC mutations should be performed every 6 months or year. When 
positive genotype is detected by genetic screening, or adenomatous polyps are detected 
by sigmoidoscopy, full colonoscopy should be performed to evaluate the spread of 
the disease. Several polyps should also be sampled to confirm histology. First-degree 
relatives of FAP patients, who do not have a genetic diagnosis, may be removed from 
aggressive follow-up and included in standard general population screening programs 
if there is no polyp detected until 40 years of age on screening [54]. Screening of the 
upper gastrointestinal tract should be performed at the time of diagnosis, or before 
25 years of age. In later periods, it should be done while the colon is being evaluated. 
Thyroid cancer is rarely seen in patients with FAP. Studies have shown that thyroid 
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cancer reaches up to 2.6% and thyroid nodules up to 51.7%. Therefore, it is recom-
mended to screen thyroid gland by ultrasonography once a year [55, 56].
3.2.1 Genetic testing
Identification of the APC mutation and its type in a patient diagnosed with FAP 
facilitates screening of other family members as well as recognition of possible phe-
notypic lesions that may result from different APC mutations. Commonly accepted 
indications for genetic testing include FAP cases, FAP in first degree relatives, APC 
mutation in first degree relatives, at least 10 cumulative colorectal adenomas, extra-
colonic involvement of FAP and multiple adenomas with colorectal cancer family 
history but without a FAP trait in the family [36].
3.2.2 Treatment
3.2.2.1 Medical treatment and chemoprevention
In cases with FAP non-steroid anti-inflammatory drugs (NSAIDs) are thought to 
achieve regression in number and size of polyps [57, 58]. The most commonly used 
agents for this purpose are sulindac and celecoxib. The role of chemopreventive 
agents in FAP patients is controversial, because the effects of these agents on cancer 
prevention are unclear.
3.2.2.2 Surgical treatment
Prophylactic colectomy should be performed in all cases with FAP. The timing of 
surgery is planned according to the number of polyps, number of adenomas, pres-
ence of dysplasia, size of polyps, symptoms and characteristics of the patient. In 
cases with mild to moderate polyposis and no other risk factors (low risk of cancer), 
surgery can be done at mid-puberty. However patients should continue to undergo 
annual CRC surveillance with colonoscopy while awaiting colectomy. Surgery 
should be performed in patients with severe polyposis, dysplasia, and polyp greater 
than 5 mm and in symptomatic cases without any time loss after diagnosis [58].
Surgical treatment options include subtotal colectomy with ileorectal anastomo-
sis (IRA), total proctocolectomy with ileal pouch-anal anastomosis (IPAA), or total 
proctocolectomy and permanent ileostomy. Total proctocolectomy and permanent 
ileostomy is preferred in cases of rectal tumor that involved the sphincter complex, 
and in cases which IPAA is not technically feasible. Functional outcomes (qual-
ity of life) and the risk of developing rectal cancer, which is the result of leaving 
the rectum in place, are important in the selection of anorectal anastomosis or 
IPAA. Patients with a few rectal polyps which can be controlled endoscopically are 
ideal for IRA. Chemoprevention is recommended for these patients in the post-
operative period. Since colon cancer mostly develops in proximal colon in AFAP 
patients, total abdominal colectomy and IRA is ideal for this group [58–60].
Risks of developing rectal cancer in the 10th and 25th years in patients undergo-
ing IRA are 4–8% and 26–30% respectively [59, 60]. It is known that adenoma or 
cancer may develop in patients with IPAA, even in those with end ileostomy [61]. 
Therefore, the remaining rectum or pouch should be examined endoscopically at 
6 months or 1 year intervals after whichever method is preferred (IPAA, IRA). IRA 
should be avoided in cases with family history of desmoid tumor, and IPAA should 
be preferred. Because in the case of a cancer or polyposis that may develop later 
in the rectum, revision of IRA to IPAA would be technically very difficult due to 
mesenteric desmoids that may develop [54].
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3.3 MutYH-associated polyposis (MAP)
The number of polyps may range from 0 to 1000, but it is known that MAP 
usually contains less adenomatous polyps than FAP. MAP is an autosomal recessive 
disease. There is a biallelic mutation of the MutYH (MYH) gene on chromosome 
1 [62]. MAP usually occurs in fifth or sixth decade with a polyp number of 10–100 
[62, 63]. There are insufficient data on extraintestinal manifestations. However, 
gastric and duodenal polyps may be found in individuals with MAP. Unlike FAP, 
there is no association with desmoids, osteomas, and CHRPE in MAP [63].
MAP should be suspected in individuals with 10 or more cumulative adenomas 
as in other adenomatous polyposis syndromes. Germline MYH testing is recom-
mended to those who have a family history of colorectal cancer or polyposis in 
recessive pattern, or who have a clinical FAP or AFAP phenotype but a negative APC 
mutation test result. In patients with biallelic MUTYH mutations, the cumulative 
lifetime risk of developing colorectal cancer is 75% in men and 72% in women by 
age 70 [64]. Most of the patients with MAP are diagnosed when they have cancer, 
but it is recommended to perform a colonoscopy every one to two years to individu-
als with known biallelic mutations, starting at 25–30 years of age [36].
CRC, adenomatous polyp with high-grade dysplasia that cannot be removed 
endoscopically, and a great number of polyps that cannot be controlled endoscopi-
cally are indications for surgery. It is recommended to remove the newly developed 
polyps by performing at least annual colonoscopy in patients not eligible for 
surgery. Surgical options include subtotal colectomy with IRA, total abdominal 
colectomy, or proctocolectomy with IPAA [63, 64].
4. Clinical findings of colon cancer
Patients frequently present with changes in bowel habits, rectal bleeding, anemia, 
and abdominal pain accompanying these findings. Patients may also suffer from 
weight loss, fatigue, nausea, vomiting, obstruction and perforation [65–69]. Clinical 
findings vary according to the tumor location. Abdominal pain, which can be seen 
in all localizations, is the most common clinical manifestation. The most common 
symptoms in right colon tumors are blunt, permanent lower quadrant pain and ane-
mia of iron deficiency due to occult hemorrhage, fatigue, and anorexia and weight 
loss. Sometimes, a mass can be palpated in the lower right quadrant [24, 68, 69].
In the left colon, the diameter is smaller (especially sigmoid colon) and the 
content is solid. In addition, left colon cancers are scirrhous and annular. Therefore, 
obstructive symptoms are common. Obstruction may lead to perforation and 
peritonitis. According to Laplace’s law, the most likely location of perforation as 
a result of obstruction of the sigmoid colon is the cecum of which the diameter is 
largest. A change in bowel habits and a progressive decrease in stool diameter may 
be the first symptoms. While rectal bleeding may be a finding as occult blood in 
feces on the right side, it may occur as hematochezia on the left side. In the presence 
of iron deficiency anemia in an adult male or postmenopausal woman, the diagnosis 
of colon cancer should be absolutely ruled out [67–70].
Patients may also present with metastatic disease. At the time of presentation, 
metastatic disease is detected in approximately 20 percent of patients in the United 
States [70]. Advanced, or often metastatic disease should be suspected in case of the 
presence of abdominal distention, ascites, early satiety, right upper quadrant pain, 
periumbilical nodules, or supraclavicular lymphadenopathy.
Colon cancer can spread in 4 different ways; directly through the neighbor-
hood, lymphatic route, hematogen route, and through the peritoneal cavity by 
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gravity (seeding) (Figure 4). It should be remembered that tumor may also 
spread by implantation due to manipulation at the time of surgery. The most 
common metastasis is in the regional lymph nodes. The most important fac-
tor determining lymph node involvement is the T category. While lymph node 
metastasis is 5–20% in T1–T2 tumors, in T3–T4 tumors lymph node involvement 
increases to more than 50%. Tumor differentiation, presence of lymphovascular 
invasion and tumor size are other factors. Hematogenous spread occurs with 
portal system and the most common site for metastasis is the liver. The other 
common sites for metastasis after liver is the lung and bones. Seeding is caused 
by the placement of free tumor cells in the omentum, periton (peritoneal carci-
nomatosis), rectovesical pouch (Blumer’s shelf tumors), and ovary (Krukenberg 
tumors) [70, 71].
5. Diagnosis and preoperative evaluation in colon cancer
Colon cancer may be suspected from vague but suspicious symptoms and signs, 
or sometimes, especially asymptomatic CRC, may only be revealed by routine 
screening. Anamnesis, physical and rectal examination are valuable in diagnosis. 
If there is a suspicion of CRC in the patient after anamnesis and physical examina-
tion, the first diagnostic test should be colonoscopy or flexible sigmoidoscopy. In 
addition, barium enema and computed tomography colonography (CTC) may be 
performed, if necessary.
The most accurate and preferred diagnostic test for colon cancer is colonoscopy 
since it can be used for detecting and sampling of lesions along the large bowel, 
examination of lesions by direct observation, treatment in appropriate patients, 
and detection of synchronous tumors. Synchronous CRCs occur in 4–5% of patients 
[71, 72]. In some individuals, a minority of neoplastic lesions are nonpolypoid and 
flat, and may be more challenging to detect by colonoscopy. However colonoscopy 
is still more sensitive in this situation than barium enema or CTC [72].
Flexible rectosigmoidoscopy can be used for diagnostic purposes as well. It is 
mostly recommended for screening of CRC every 5 years, starting at the age of 50 
with annual fecal occult blood test. In recent years there is an increase in right-sided 
or proximal colon cancers. Because of this and the likelihood of synchronous CRCs, 
it should be considered that flexible sigmoidoscopy may be an inadequate test for 
diagnosis of a patient suspected of having a CRC [72, 73].
Figure 4. 
Colon cancer dissemination.
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Computerized tomography is the most frequently used test for staging pur-
poses. Positron emission tomography has no place in routine staging and screen-
ing. However, in suspicious cases, tumor and fibrous tissue are well separated. 
Abdominal ultrasonography has no place in the diagnosis of colon cancer [71].
Routine laboratory tests including complete blood count, liver function tests, 
etc. have no role in diagnosis. However In the presence of iron deficiency anemia 
in an adult male or postmenopausal woman, colon cancer should be ruled out. 
Although liver function tests has no role in diagnosis of liver metastasis, the 
increase in liver enzymes in patients with colon cancer should be taken into consid-
eration to scan for metastasis [71, 72].
It is known that some tumor markers, especially CEA (carcinoembryonic anti-
gen), are associated with CRC. Nevertheless, tumor markers such as CEA and CA 
19-9 appears to have a low diagnostic yield to diagnose primary CRC, since these 
markers have low sensitivity for early-stage disease and may also increase in some 
benign diseases. However, both markers have prognostic significance. High CEA 
suggests the presence of metastasis. In addition, after appropriate treatment increase 
in CEA level in follow-up should be assessed in favor of recurrence or metastasis [73].
6. Staging
The local features (size, invasion, lymph node involvement) of the tumor are 
important in determining the resection margin. Therefore, preoperative clinical 
staging should be done properly. Physical examination and radiological tests are 
used for accurate clinical staging. It should not be forgotten that the accuracy of 
radiological detection of the stage is 85–90%, even in the best hands. Definitive 
staging can only be performed by pathological examination [74].
Pathologic staging in colorectal cancers is based on tumor depth, lymph node 
involvement, and the metastatic status. Dukes and Astler-Coller classifications 
are no longer used, instead the TNM staging system is preferred [74]. The most 
recent (8th edition) revision of the TNM staging classification contains few changes 
compared with the earlier edition (7th edition). T categories have been revised. 
Tis in the AJCC 8th edition refers only to intramucosal carcinoma, a lesion with 
involvement of lamina propria with no extension through muscularis mucosae. T4 
is defined as tumor exceeds the visceral peritoneum either by continuous invasion 
or perforation of the tumor. N categories have not changed. Lastly, the M category 
has been expanded, with the addition of M1c for peritoneal metastases. Therefore, a 
new stage, IVc, have been added in stage grouping.
Stage of the disease is the most important prognostic parameter that determines 
the type of surgery and postoperative treatment options in colorectal cancers. 
Because of the different lymphatic drainage on the intestinal wall, colorectal cancer 
gains potential to make metastasis only when there is submucosal invasion. For 
this reason, colorectal carcinoma is diagnosed only in the presence of submucosal 
invasion [74].
Dukes staging:
Dukes A: Tumor is limited in the bowel wall.
Dukes B: Invasion through the bowel wall but no lymph node involvement.
Dukes C: Lymph node involvement.
Dukes D: Distant metastasis.
Modified Astler-Coller staging:
A: Tumor is limited to mucosa.
B1: Muscularis propria is invaded but not exceeded.
B2: Invades through muscularis propria (subserosal dissemination).
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B3: Lesion involves adjacent organs.
C1: B1 + lymph node involvement.
C2: B2 + lymph node involvement.
C3: B3 + lymph node involvement.
D: Distant metastasis.
7. Treatment
Colon cancers mostly develop from polyps. Although curative treatment of 
localized colon cancer is surgery, endoscopic polypectomy is enough when carci-
noma in situ or severe dysplasia presents on the polyp surface. However, surgery 
should be considered for the treatment of colon cancer especially in patients a 
polyp that cannot be removed endoscopically, and if there is continuity in resection 
margin after polypectomy [75].
In the last decade, there have been major changes in colorectal cancer manage-
ment. Total mesorectal excision and neoadjuvant chemoradiotherapy in rectum 
cancers resulted in significant reductions in morbidity, mortality, and recurrence 
rates. Recently, complete mesocolic excision (CME) and central vascular ligation 
(CVL) (open or laparoscopic) has been described in colon cancer treatment to 
achieve similar oncological results. In 2007, Hohenberger published the first article 
on CME with CVL for colon cancer and which was later published in English [75, 76]. 
The aim of CME with CVL method is to create an intact protective mesocolic fascia 
and avoid tumor spread within peritoneal cavity by dissection of the visceral fascia 
from the parietal (retroperitoneal) plane (Figure 5). The origin of colonic vessels is 
well exposed and ligated centrally at their origin using this technique. The specimens 
are characterized by a greater distance from the tumor to the high vascular tie, 
higher distance from the closest bowel wall to the high vascular tie, longer length of 
the colon and larger area of mesentery. Thus, maximum lymphatic tissue harvest is 
achieved [76, 77]. Increase in the patients who have a high number of lymph nodes, 
decrease in perioperative morbidity, reduction in local recurrence, and advancement 
in colon cancer-specific survival rate have been shown in recent studies regard-
ing CME [76, 78–80]. This technique is a matter of controversy in colon surgery. 
Because longer operating times, autonomic nerve injury, and major vascular damage 
are disadvantages of routine implementation of CME. Although the technique has 
improved oncologic data, routine implementation of CME may decrease health-
related quality of life (QoL) [76, 80].
Figure 5. 
Complete mesocolic excision and central vascular ligation for the treatment of extended right hemicolectomy 
specimen.
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Figure 6. 
Resection margins in cecum and ascending colon tumors.
Surgical resection of the tumor is the main curative treatment option. The colon 
segment where the tumor is located, the mesentery that contains the lymphatic drain-
age, and, if there is invasion, adjacent organs should be removed in one piece without 
deteriorating tumor integrity. If the tumor cannot be removed surgically, palliative 
surgical procedures such as limited resections, proximal diversion ostomies (colos-
tomy, ileostomy), or bypass surgeries may be applied to relieve symptoms or prevent 
possible complications [79]. Right hemicolectomy (extended or not), transverse 
colectomy, left hemicolectomy (extended or not) sigmoid colectomy, and subtotal 
or total colectomy are preferred for surgical treatments of colon tumors according 
to involved bowel segment. Surgical intervention may be performed conventional 
(open) or laparoscopic, provided that it conforms to oncologic principles [80].
7.1 Cecum and ascending colon tumors
Right hemicolectomy is performed as a standard surgical treatment option in 
the right-sided colon tumors. In this operation, right branch of the middle colic, 
ileocolic, and right colic vessels are ligated as high as possible. The ascending colon, 
the hepatic flexure, the first third of the transverse colon, and distal part of the 
terminal ileum is resected (Figure 6). Then, ileocolonic anastomosis is performed 
between ileum and transverse segment of the colon.
7.2 Hepatic flexure tumors
To remove the entire lymphatic network, CVL of the middle colic, right colic, 
and ileocolic vessels is performed. This operation is called extended right hemi-
colectomy (Figure 7). When compared to the left hemicolectomy, the amount of 
transverse colon that is resected increases and only distal 1/3 of the transverse colon 
is left. An anastomosis should be avoided in areas of unreliable blood supply such 
as splenic flexure. In this case resection margins should be expanded and splenic 
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flexure should be removed as well. Finally, anastomosis is created between the 
ileum and the proximal end of the remaining colon.
7.3 Transverse colon tumors
The choice of surgery type in transverse colon tumors may be a matter of debate. 
The arterial supply of the transverse colon is provided by right colic and left colic 
and middle colic arteries. Ischemia usually does not occur in the anastomosis at 
the hepatic flexure due to branches from ileocolic and right colic arteries, even if 
middle colic artery is centrally ligated. However when middle colic artery is ligated, 
arterial supply of splenic flexure is only provided by left colic artery and there is 
an ischemia risk in the anastomosis at the splenic flexure. Therefore, transverse 
colectomy could be performed by CVL of the middle colic and left colic vessels for 
mid-transverse colon tumors. In this procedure, distal ascending, hepatic flexure, 
transverse, splenic flexure, and proximal descending colon are resected (Figure 8). 
Moreover, it is recommended surgical resection of the ascending colon and cecum 
to perform ileosigmoidal anastomosis because it is technically difficult to create an 
anastomosis between ascending and sigmoid colon. Consequently, it is necessary to 
consider both the arterial circulation and the lymphatic drainage in the selection of 
the operation type in transverse colon tumors.
7.4 Splenic flexure tumors
Extended left hemicolectomy is recommended for splenic flexure tumors, as 
lymphatics may drain to the lymph nodes along the inferior mesenteric artery 
(IMA) and middle colic artery. The central ligation of the middle colic artery and 
IMA requires to remove all entire bowel from the proximal transverse colon to the 
proximal rectum. At the end of the surgical procedure, an anastomosis is performed 
between proximal transverse colon and proximal segment of the rectum (Figure 9).
Figure 7. 
Resection margins in hepatic flexure tumors.
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7.5 Descending colon tumors
Left hemicolectomy is recommended in patients with ascending colon tumor. 
IMA is centrally ligated without preserving the left colic artery. Splenic flexure, 
descending and sigmoid colons are removed. Then, anastomosis is established 
between transverse colon and proximal rectum (Figure 10).
Figure 9. 
Resection margins in splenic flexure tumors.
Figure 8. 
Resection margins in transverse colon tumors.
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7.6 Sigmoid colon tumors
The appropriate operation for these tumors is sigmoid colon resection. IMA is 
centrally ligated while left colic artery is preserved. Sigmoid colon is then removed 
and colorectal anastomosis is created (Figure 11).
Figure 10. 
Resection margins in descending colon tumors.
Figure 11. 
Resection margins in sigmoid colon tumors.
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8. Prognosis
Pathologic stage at presentation is the strongest prognostic factor. In patients 
with stage 1 colon tumor, the 5-year survival rate is approximately 90% while it 
drops to 15% in stage 4 patients [2]. Despite a curative surgery and modern adjuvant 
treatments, recurrence develops in approximately 40% of stage 2 and 3 patients 
[81]. Almost all recurrences develop within the first 5 years, and most of them are 
seen within the first 3 years [82].
Besides pathologic staging, the most important prognostic factors for CRC are 
histologic grade of differentiation, extramural tumor deposits, lymphovascular and 
perineural invasion, the preoperative carcinoembryonic antigen (CEA) level, MSI, 
and RAS and BRAF mutations. The local extent of disease independently influences 
survival [83, 84]. However tumor size has no significant impact on prognosis [84, 
85]. One of the adverse prognostic factors is residual tumor after resection [86, 
87]. There are three types of R designation for residual tumors in non-metastatic 
patients: R0 resection, complete resection of the tumor with histologically negative 
margins, R1 resection, incomplete tumor resection with positive microscopic margin 
involvement, R2 resection, and incomplete resection with macroscopic margin 
involvement [74].
Regional lymph node metastasis is the other important determinant of prognosis 
after distant metastasis. Lymph node involvement is alone an indication for post-
operative adjuvant therapy to reduce the metastasis risk. Although the number of 
positive lymph nodes involved is a crucial predictor of outcome [74, 88], relation-
ship between total number of the lymph nodes and the prognosis is not well under-
stood. However, increased number of total lymph nodes in the surgical specimen 
may be an indicator for the quality of the surgical procedure [88].
Tumor deposits are separate nodules of tumor within the pericolic fat or mesen-
tery. In the TNM staging they are staged as N1c which means there are no regional 
lymph nodes involved but the subserosa, mesentery, or nonperitonealized pericolic 
tissues contains tumor deposits(74). These deposits are strong adverse prognostic 
determinants, and there is a relation between extramural extranodal tumor deposits 
and extramural venous invasion [89, 90]. Lymphovascular involvement which is 
tumor invasion into veins, especially extramural veins, or lymphatics is thought to 
be an adverse prognostic factor [91–93]. Perineural invasion is also associated with 
an elevated risk of recurrence and poor prognosis [94, 95].
Several studies have provided evidence that preoperative high CEA levels have 
adverse impact on prognosis for colon cancer. It has been determined that higher 
CEA levels increase overall mortality and even prognosis is similar or worse in 
patients with higher CEA levels but lower stages when compared to patients with 
higher stages but lower CEA levels according to AJCC TNM staging [96, 97].
Metastatic disease is another significant clinical problem in patients with CRCs. 
The liver, lungs, lymph nodes, and peritoneum are the most frequently involved 
organs. Major developments in chemotherapy have increased survival rates in 
a serious manner, but 5-year survival rates are below 20% without resection or 
ablation of metastasis. Five-year survival rates are 36–58% in patients undergoing 
partial hepatectomy for hepatic metastases [98–102]. Lung involvement is less 
common than liver metastasis, but in carefully selected patients metastasectomy is a 
favorable option for treatment [102].
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